NO20082636L - Anvendelse av DHA og ARA for fremstilling av en sammensetning for forebygging eller behandling av fedme - Google Patents

Anvendelse av DHA og ARA for fremstilling av en sammensetning for forebygging eller behandling av fedme

Info

Publication number
NO20082636L
NO20082636L NO20082636A NO20082636A NO20082636L NO 20082636 L NO20082636 L NO 20082636L NO 20082636 A NO20082636 A NO 20082636A NO 20082636 A NO20082636 A NO 20082636A NO 20082636 L NO20082636 L NO 20082636L
Authority
NO
Norway
Prior art keywords
dha
ara
obesity
prevention
treatment
Prior art date
Application number
NO20082636A
Other languages
English (en)
Inventor
Thomas J Brenna
Joshua C Anthony
Steven C Rumsey
Kristin Morris
Original Assignee
Cornell Res Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Res Foundation Inc filed Critical Cornell Res Foundation Inc
Publication of NO20082636L publication Critical patent/NO20082636L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dairy Products (AREA)

Abstract

Det beskrives en ny fremgangsmåte for forebyggelse eller behandling av fedme hos et individ. Fremgangsmåten omfatter administrering av en terapeutisk effektiv mengde DHA og ARA, alene eller i kombinasjon med hverandre, til individet.
NO20082636A 2006-02-28 2008-06-05 Anvendelse av DHA og ARA for fremstilling av en sammensetning for forebygging eller behandling av fedme NO20082636L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77734506P 2006-02-28 2006-02-28
PCT/US2007/004421 WO2007100561A2 (en) 2006-02-28 2007-02-19 Use of dha and ara in the preparation of a composition for preventing or treating obesity

Publications (1)

Publication Number Publication Date
NO20082636L true NO20082636L (no) 2008-09-29

Family

ID=38220602

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082636A NO20082636L (no) 2006-02-28 2008-06-05 Anvendelse av DHA og ARA for fremstilling av en sammensetning for forebygging eller behandling av fedme

Country Status (12)

Country Link
US (1) US20070203237A1 (no)
EP (1) EP1988888A2 (no)
KR (1) KR20080103972A (no)
CN (1) CN101389322A (no)
BR (1) BRPI0708378A2 (no)
CA (1) CA2642969A1 (no)
IN (1) IN2008DE06532A (no)
MX (1) MX2008010888A (no)
NO (1) NO20082636L (no)
RU (1) RU2456985C2 (no)
TW (1) TWI388319B (no)
WO (1) WO2007100561A2 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007100562A2 (en) * 2006-02-28 2007-09-07 Bristol-Myers Squibb Company Use of dha and ara in the preparation of a composition for reducing triglyceride levels
US20070203235A1 (en) * 2006-02-28 2007-08-30 Rosales Francisco J Method for preventing or treating anemia
CA2664206C (en) 2006-10-03 2015-03-17 Michael D. Myers Meal replacement compositions comprising dha and weight control method
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
WO2010112429A1 (en) 2009-04-01 2010-10-07 Nestec S.A. Reduction of risk of obesity
WO2010134800A1 (en) * 2009-05-19 2010-11-25 N.V. Nutricia Human milk fortifier with high protein and long chain poly unsaturated fatty acids for improving body adipose tissue distribution
US20110131132A1 (en) 2009-11-27 2011-06-02 Eazybreak Oy System and method for managing subscriber account
ES2555032T3 (es) 2010-01-19 2015-12-28 Mjn U.S. Holdings Llc Compensación nutricional para dieta de tipo occidental
CN101878819B (zh) * 2010-07-20 2012-02-01 澳优乳业（中国）有限公司 一种含脂联素的婴幼儿配方奶粉及其制备方法
US10251928B2 (en) 2014-11-06 2019-04-09 Mead Johnson Nutrition Company Nutritional supplements containing a peptide component and uses thereof
US11109607B2 (en) 2013-11-18 2021-09-07 Gary Hall Oil-based compositions for enhancing oral health and general wellness in humans
CN105992520A (zh) * 2013-12-19 2016-10-05 雅培公司 包含水解蛋白质的营养组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2033193B1 (es) * 1990-10-30 1994-01-16 Ganadera Union Ind Agro Mezcla grasa para nutricion infantil y de adultos.
US20030064950A1 (en) * 2001-02-23 2003-04-03 Ntambi James M. Methods for reducing body fat and increasing lean body mass by reducing stearoyl-CoA desaturase 1 activity
TW200412942A (en) * 2002-08-06 2004-08-01 Abbott Lab Appetite control method
US6753350B1 (en) * 2003-03-24 2004-06-22 Bristol-Myers Squibb Company Method to reduce the incidence of intraventricular hemorrhage in preterm infants
WO2005063050A1 (en) * 2003-12-19 2005-07-14 Abbott Laboratories Method of increasing lean body mass and reducing body fat mass in infants
SE0303513D0 (sv) * 2003-12-19 2003-12-19 Pronova Biocare As Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof

Also Published As

Publication number Publication date
RU2008134874A (ru) 2010-04-10
EP1988888A2 (en) 2008-11-12
KR20080103972A (ko) 2008-11-28
CA2642969A1 (en) 2007-09-07
BRPI0708378A2 (pt) 2011-06-07
TW200744573A (en) 2007-12-16
WO2007100561A2 (en) 2007-09-07
US20070203237A1 (en) 2007-08-30
RU2456985C2 (ru) 2012-07-27
MX2008010888A (es) 2008-09-03
IN2008DE06532A (no) 2008-10-24
TWI388319B (zh) 2013-03-11
CN101389322A (zh) 2009-03-18
WO2007100561A3 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
NO20082636L (no) Anvendelse av DHA og ARA for fremstilling av en sammensetning for forebygging eller behandling av fedme
ATE551063T1 (de) Verwendung von bifidobacterium longum zur prophylaxe und behandlung von entzündungen
WO2011069141A3 (en) Interferon therapies in combination with blockade of stat3 activation
WO2008054695A3 (en) Composition and method for etiological treatment and prevention of diseases and/or complications associated with chronic glucose metabolism destabilization
WO2009079451A3 (en) Compositions and methods of promoting wound healing
NO20083885L (no) Fremgangsmate for behandling av inflammatoriske sykdommer
WO2007103719A3 (en) MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
WO2009114810A3 (en) Use of ellagitannins as inhibitors of bacterial quorum sensing
MX2010005676A (es) Metodo para retrasar el comienzo de esclerosis multiple clinicamente definida.
BRPI0722054A2 (pt) Composição, kit, e métodos para diminuir um efeito colateral de tratamento com um inibidor da calcineurina, para aumentar um efeito terapêutico de um inibidor da calcineurina e para mudar a concentração de tacrolimus ou um análogo de tacrolimus em um compartimento fisiológico.
RS52867B (en) GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS
AU2008267058A8 (en) Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
WO2007012022A3 (en) Unit dose form with ibuprofen-famotidine admixture
NZ599605A (en) Hemostatic compositions and therapeutic regimens
WO2009154840A3 (en) Compositions and methods using stem cells in cutaneous wound healing
ATE494889T1 (de) Pharmazeutische kombination mit 3- (3- dimethylamino-1-ethyl-2-methyl-propyl)-phenol und paracetamol
WO2008070859A3 (en) Treatment of skin conditions by dickkopf1 (dkk1)
DK2043637T3 (da) Fremgangsmåder og medikamenter til administrering af ibuprofen
ATE457729T1 (de) Verwendung von allopurinol zur behandlung von palmarer/plantarer erythrodysästhesie
WO2008112773A3 (en) Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension
WO2008012796A3 (en) Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation
TNSN08385A1 (en) Delayed-release glucocorticoid treatment of rheumatoid disease
WO2009006246A8 (en) Use of tight junction antagonists in the treatment of acute long injury and acute respiratory distress syndrome
WO2008063563A3 (en) Methods of treating keratin hyperproliferation disorders using mtor inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application